FORMULATION OPTIMIZING COURSE OF HEMODIALYSIS IN RENAL INSUFFICIENCY PATIENTS Russian patent published in 1999 - IPC

FIELD: urology. SUBSTANCE: formulation contains 10-20 mg of relanium and 10-20 ml of sodium hydroxybutyrate (2-4 g). Instead of relanium (Polish production), its pharmacological analogs such as seduxen (Hungary) or sibason (Russia) can be utilized. Single dose of relanium and its pharmacological analogs varies within therapeutic range from 5 to 20 mg. EFFECT: prevented development of hemodialysis adverse effects and complications or reduced their intensity owing to stress-protection, decongestant, and antihypoxic activity of formulation components. 3 tbl